Press Release Distribution
Pricing
Customer Support
(800) 998-2927
Login
Log In
All Categories
Business
Entertainment
Health
Finance
Other
Tagged
immunologics
Press Release
Jan 6, 2016
H2Biologics Licenses Exclusive Rights to Develop SD1-Granzyme B Drug Conjugate for Treatment of Tumors.
H2Biologics Licenses Worldwide, Exclusive Rights to Develop SD1-Granzyme B Drug Conjugate for Treatment of Mesothelin-expressing Tumors.
Read More
First
Prev
1
Next
Last